• Catalyst4, a 10% owner of Maplight Therapeutics, reported open-market purchases totaling 1,209,225 voting common shares.
• Purchases were priced between USD 10.74 and USD 13 per share, based on reported trade prices and weighted averages.
• Beneficial ownership rose to 20,906,689 voting common shares, held indirectly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001900201-26-000003), on July 30, 2026, and is solely responsible for the information contained therein.